Home » Topics » HIV/AIDS, BioWorld Science

HIV/AIDS, BioWorld Science
RSS

Sequus' Caelyx approved by European Commission

June 28, 1996

Hybridon's GEM-132 to undergo clinical trials

June 28, 1996

Remune covered under Finnish patent

June 28, 1996

Viramune receives accelerated FDA approval

June 28, 1996

Merck & Co. claims process for synthesizing HIV protease inhibitors

June 28, 1996

Y-ART-3: Promising HIV treatment candidate

June 21, 1996

HIV protease inhibitors from Warner-Lambert

June 21, 1996

Alpha-glucosidase inhibitors from Seikagaku Kogyo

June 21, 1996

Pediatric clinical trials for Remune commence

June 14, 1996

GR-92754: Most effective DHFR inhibitor

June 14, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...